Post-mortem specimens from the Stanley Foundation Neuropathology Consortium, which contains matched samples from patients with schizophrenia, bipolar disorder, non-psychotic depression and normal controls (n = 15 per group), have been distributed to many research groups around the world. This paper provides a summary of abnormal markers found in prefrontal cortical areas from this collection between 1997 and 2001. With parametric analyses of variance of 102 separate data sets, 14 markers were abnormal in at least one disease. The markers pertained to a variety of neural systems and processes including neuronal plasticity, neurotransmission, signal transduction, inhibitory interneuron function and glial cells. The data sets were also examined using the non-parametric Classification and Regression Tree (CRT) technique for the four diagnostic groups and in pair-wise combinations. In contrast to the results obtained with analyses of variance, the CRT method identified a smaller set of nine markers that contributed maximally to the diagnostic classifications. Three of the nine markers observed with CRT overlapped with the ANOVA results. Six of the nine markers observed with the CRT technique pertained to aspects of glutamatergic, GABA-ergic, and dopaminergic neurotransmission.
Introduction
The Stanley Foundation Brain Collection was established in 1994 in order to develop an international post-mortem tissue resource for studies of the major psychiatric illnesses (schizophrenia, bipolar disorder, and major depression). The collection is maintained within the Department of Psychiatry of the Uniformed Services University of the Health Sciences (USUHS) in Bethesda, Maryland, and presently consists of over 400 specimens. Brain specimens were obtained at autopsy by medical examiners in several US cities. Details regarding the selection of cases, collection of clinical data, diagnostic procedure, and processing of postmortem tissue have been published previously. 1 The Stanley Foundation Neuropathology Consortium is a selection of matched specimens from within the larger Brain Collection. It contains 15 cases each from individuals with schizophrenia, bipolar disorder, major depressive disorder without psychotic features, and normal controls. These groups are matched as shown in Table 1 and were all collected between September 1994 and February 1997. Table 2 contains data regarding cause of death, presence of psychosis, family history of psychosis, lifetime exposure to antipsychotic drugs, and co-morbid substance abuse.
The 60 matched specimens that constitute the Neuropathology Consortium have been made available to research groups around the world. All investigators receive coded tissue samples and perform their assays in a blinded fashion. Investigators receive the code after submitting their data to the Stanley Foundation and they are then free to individually interpret and publish their findings. Data obtained from researchers using this tissue are also stored in a master database within the Stanley Foundation. The Stanley Consortium is therefore the single most extensively characterized collection of pathological specimens from patients with major mental illnesses, and integrative analyses of available data will be performed in an ongoing manner.
In previous publications, 2, 3 we have summarized prefrontal data produced with a subset of the current data. These publications summarized available prefrontal data with analyses of variance and with linear discriminant function. While heuristic for exploratory analyses, these approaches require the assumption of normally distributed data and may produce spurious Side of brain frozen 6 R, 9 L 8 R, 7 L 6 R, 9 L 7 R, 8 L A = Asian, AA = African-American, C = Caucasian. results due to multiple comparisons. We have therefore attempted to summarize an enlarged prefrontal data set with the Classification and Regression Tree (CRT) technique, a hierarchical, non-parametric method. CRT analyses have been successfully employed in other branches of medicine, in which multiple variables obtained from individual subjects can be grouped together to improve classification into diagnostic or prognostic groups.
4,5

Methods
Tissue samples
For the purposes of this summary, all data collected from Brodmann's areas (BA) 8, 9, 10 or 46 were exam-
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ined. As of April 2001, data sets for 102 markers had been returned. The markers included in this summary are listed in Table 3 . Data on these markers were produced with a variety of techniques (radioligand binding, immunoblot, or in situ hybridization, for example) and were performed using several possible tissue conditions (frozen or fixed, sections or tissue blocks). Fixed and frozen sections contained portions of both the superior and middle frontal gyri, corresponding to BA 9 and 46. Blocks of tissue for homogenate-based assays were obtained from BA 8, 9, 10 or 46, but occasionally contained tissue from more than one Brodmann's area. Markers were only included if the assays used to measure them produced quantitative measurements of continuous variables and if there were data available for an arbitrarily defined majority of cases (n Ͼ 54, or Ͼ90% complete data). Data summarized in this paper do not represent the complete set of data available for prefrontal specimens, as work in a number of laboratories is still ongoing. Several markers in Table 3 were measured with different 'levels'. When a single measurement was obtained from the full cortical width, the marker is listed in Table 3 as having one level. When measurements were made in more than one cortical layer, the marker is listed in Table 3 as having levels Ͼ1. The calcium-binding proteins (calbindin, calretinin, and parvalbumin) were measured in more than one Brodmann's area and in multiple cortical layers. Thus, they are represented in Table 3 as having been measured in 2 × 5 'levels'. If measurements from multiple cortical layers and Brodmann's areas are considered separately, then 284 variables were available for this analysis.
Analysis of variance
All markers listed in Table 3 were first compared with individual analyses of variance (ANOVAs). When values for multiple cortical layers, or multiple prefrontal regions, were obtained with the same marker, a MANOVA was performed with diagnosis as a betweengroup factor and cortical level as a within-group factor. Post-hoc Newman-Keuls tests were performed to evaluate statistically significant ANOVAs. ANOVAs were performed with software from Statistica (StatSoft, Tulsa, OK, 1995).
Classification and regression trees (CRT)
CRT is a stepwise, nonparametric procedure that uses exhaustive computerized searches and sorting techniques to identify useful tree-structures for classification of data from several groups. With the CRT technique, the classification potential of variables is assessed relative to a split or cut-point. The single best predictor (the one whose optimal cut-point maximizes the number of correct classifications among the diagnostic categories) is selected as the starting variable at the top of a hierarchical tree. Subjects with values less than the cut-point move to one category, while those with values greater than the cut-point move into a second box of the hierarchical tree. Cut-points are then assessed in a step-wise fashion for the remaining predictors. A classification tree is generated that grows until maximal classification is achieved, or further splitting is judged to be not 'cost-effective'.
CRT analysis was performed with commercially available software (Salford Systems, San Diego, CA, 1999). This software produces a 'maximal tree' in which the maximal separation of diagnostic groups is achieved. The maximal tree is then pruned to an 'optimal tree', which is the best tree based on predictive accuracy and on the law of diminishing returns. In other words, variables are excluded when the 'cost' of adding in additional variables is high relative to the number of additional correct classifications. Only the optimal trees derived from these data sets are presented here. The details regarding cost-estimation procedures with the CRT software are available from the manufacturer (www.salford-systems.com) and have been published previously. 6 The CRT software produces two classification matrices. The first matrix produced is the 'learning model' in which all the data points are considered together. In a 'test' model, the CRT software considers 90% of the data, builds a model, and uses the remaining 10% of data to test the model. The process is repeated ten times such that each part is held in reserve once as a test sample. The results of these ten runs are then combined to form the test model classification matrix. This test procedure is an attempt to estimate the independent predictive accuracy of the tree. Only the results of the test models of the CRT analyses are presented here.
CRT analyses were performed in two ways. The first analysis combined the data of all four diagnostic groups. Secondly, since there is considerable pheno-typic overlap between the three major psychiatric disorders, pair-wise CRTs were performed for each of the six possible combinations of two diagnostic categories.
Analysis of covariance
There were 11 descriptive variables available for analysis of possible confounding effects. For eight continuous descriptive variables (post-mortem interval (PMI), age, estimated lifetime exposure to neuroleptics, age of illness onset, illness duration, brain pH, brain weight, and freezer storage time), we sought significant Spearman's correlations for the abnormal molecular markers. Three non-continuous descriptive variables (hemisphere, gender, and history of substance abuse) were used as grouping variables with t-tests to evaluate their effects on abnormal molecular markers. Significant effects of descriptive variables were checked by retesting significant molecular markers with ANCOVA.
Results
Disease related effects by ANOVA
The overall results of the univariate ANOVAs are displayed in Table 3 . It should be stressed that these results may differ from those reported by individual investigators, who may have had a priori reasons to exclude some cases, or to employ different statistical methods. From the 102 univariate ANOVAs there were 14 significantly abnormal results (13.7% of the total number). Table 4 displays the post-hoc statistical significance of these 14 variables. Statistical significance and effect sizes (according to Cohen) 7 are given relative to the normal control group. The effect size is the difference between the diagnostic group mean and the control group mean in terms of the pooled standard deviation of the two groups. Effect sizes greater than 0.5 (psychiatric group mean greater than control group mean) or less than −0.5 (psychiatric group mean less than control group mean) are often considered robust in meta-analyses of biological data. When corrected for multiple comparisons, the P values reported in Table  4 do not achieve statistical significance.
Effects of continuous confounding variables on ANOVA results
Brain pH was correlated with the largest number of markers. These included glucocorticoid receptor RNA levels in layers 3-6 (rho = 0.25-0.33), non-phosphorylated (rho = 0.42) and phosphorylated cytosolic protein kinase C⑀ (rho = 0.45), and kainic acid receptor subunit 2 in layer 1 (rho = 0.39) and layer 2 (rho = 0.36). However, ANCOVA with pH as a covariate did not change the disease related effects observed in the original ANOVA for these markers. Brain pH was also correlated with dynorphin RNA level (rho = 0.28) and with calbindin level in layer 2 of BA 9 (rho = 0.33). ANCOVA with pH as a covariate failed to confirm the disease-related differences seen with ANOVA for these markers. Markers that failed to maintain diseaserelated significance with ANCOVA are indicated in Table 4 . pH was also correlated with the density of oliMolecular Psychiatry godendrocytes in layer 6 (rho = 0.38). ANCOVA with pH as a covariate confirmed significant differences for schizophrenia and bipolar disorder compared to controls, but did not confirm a difference between depressed subjects compared to controls.
Freezer storage time was the next most important confounding variable. Storage time was significantly correlated with glucocorticoid receptor RNA levels in layers 3 (rho = −0.28) and 4 (rho = −0.34), reelin RNA (rho = −0.37), GAD 67 (rho = −0.41) and cytosolic protein kinase C⑀ (rho = −0.26). However, ANCOVA with storage time as a covariate did not alter the diseaserelated differences observed with ANOVA for these markers. Storage time was also correlated with oligodendrocyte density (rho = −0.27) and with dynorphin RNA (rho = −0.43). ANCOVA with storage time as a covariate failed to confirm the disease related differences observed with ANOVA for these markers. Storage time was correlated with glucocorticoid receptor RNA level in layer 6 (rho = −0.36). ANCOVA with storage time as a covariate confirmed the disease related changes seen with ANOVA and was also associated with a new significant decrease for bipolar disorder compared to controls.
There were several significant correlations with PMI. Glucocorticoid receptor RNA levels in layers 3-6 were significantly correlated with PMI (rho = −0.26 to −0.28). However, ANCOVA with PMI as a covariate did not change the disease related effects observed in the original ANOVA. PMI was correlated with Nurr 77 protein level (rho = −0.26), dynorphin mRNA level (rho = −0.29), and phosphorylated cytosolic protein kinase C⑀ (rho = −0.26). When PMI was included as a covariate for these markers, disease-related differences could not be confirmed.
Illness onset (rho = −0.39) and illness duration (rho = −0.31) were correlated with dynorphin mRNA levels. Estimated lifetime exposure to antipsychotic drugs was correlated with calcium-stimulated phosphoinositol turnover (rho = 0.39). None of these factors, considered as covariates, altered the disease-related effects observed with ANOVA.
Effects of non-continuous confounding variables on ANOVA results
Only one variable was significantly different between left and right hemispheres of the brain. Phosphorylated cytosolic protein kinase C⑀ was expressed at higher levels in the right hemisphere compared to the left (t = 2.46, P = 0.02). However, the significant difference between subjects with schizophrenia or bipolar disorder and normal controls remained when hemisphere was controlled for with ANCOVA.
Only one variable was significantly different between genders. Females had higher levels of iNOS protein compared to males (t = 2.04, P Ͻ 0.05). The significant difference in iNOS levels observed between subjects with depression and normal controls remained when gender was controlled for with ANCOVA.
Subjects with a history of substance abuse had sig- nificantly lower levels of GFAP (t = 2.19, P Ͻ 0.05) and of dynorphin mRNA (t = 2.07, P Ͻ 0.05) compared to subjects who had not abused substances. The significant difference between subjects with bipolar disorder and normal controls for dynorphin observed with ANOVA was not confirmed when the effect of substance abuse was checked with ANCOVA. Substance abuse did not alter the disease-related differences observed for GFAP levels with ANOVA.
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Disease-related CRT results
CRT analysis on the entire prefrontal data set produced the decision tree shown in Figure 1 . The markers identified were glutamic acid decarboxylase 67 (GAD 67), NR2C glutamate receptor subunit RNA in layer 4, and glucocorticoid receptor (GR) RNA in layer 6. Forty-five percent of total cases were correctly classified, which is statistically different from correct classification of 25% of subjects by chance (binomial test, P Ͻ 0.05).
Figures 2 through 7 display the pair-wise runs of the CRT software. Sensitivity, specificity and positive predictive value were calculated for pairwise comparisons to controls, but not for comparisons between disease groups. A summary of the correct classification percentages for the pair-wise runs is given in Table 5 . All markers that contributed to correct classification in the CRT analyses are listed in Table 6 .
Bipolar disorder was best discriminated from normal ( Figure 2 ) by GAD 67 (86.7% correctly classified; binomial test from 50% chance correct classification, P Ͻ 0.001). If prefrontal GAD 67 could be viewed as a clinical test in this paradigm, it would be associated with sensitivity = 0.73, specificity = 1.0, and positive predictive value = 1.0. Depression was best discriminated from normal ( Figure 3 ) with a two-step tree containing glutamate GluR2 receptor subunit RNA in layer 6, and GR RNA in layer 6 (90% correct classification; binomial test from 50% chance correct classification, P Ͻ 0.001). These combined results are associated with sensitivity = 0.93, specificity = 0.87, and positive predictive value = 0.875.
Schizophrenia was best discriminated from normal ( Figure 4 ) by a two-step tree containing GAD 67 and GR RNA in layer 6 (83.3% correct classification; binomial test from 50% chance correct classification, P Ͻ 0.001). These combined results are associated with sensitivity = 0.87, specificity = 0.80, and positive predictive value = 0.81. Bipolar disorder was best discriminated from depression ( Figure 5 ) by a three-step tree containing GAD 67, inducible nitrogen oxide synthetase (iNOS) Molecular Psychiatry Figure 3 Pair-wise classification and regression tree for major depression compared to normal controls. and glutamic acid decarboxylase 65 (63.3% correct classification). Schizophrenia was best discriminated from depression ( Figure 6 ) with a three-step tree containing GAD 67, s-cysteinyl dopa, and alpha-synuclein (83.3% correct classification). Schizophrenia was best discriminated from bipolar disorder (Figure 7 ) by s-cysteinyl DOPAC (53.3% correct classification).
Effects of confounding variables on CRT results
Post-mortem interval was significantly correlated with GluR2 RNA levels in layer 6 (rho = −0.26) and with scysteinyl dopa levels (rho = 0.31). Age at illness onset was significantly correlated s-cysteinyl dopa levels (rho = −0.33). Brain pH was significantly correlated with glucocorticoid receptor RNA in layer 6 as noted above in the section on ANOVA results. There were no significant correlations observed for exposure to neuroleptic drugs, illness duration and brain weight. None of the non-continuous descriptive variables (hemisphere, gender and substance abuse) showed significant effects on CRT variables.
Discussion
As shown in Table 4 , 14 of 284 variables were abnormal in one or more diseases with analyses of variance. As discussed in previous work, 2 there are some generalizations that can be made about these markers. First, the markers pertain to a variety of neural systems and cellular phenotypes. Taken together, these abnormalities suggest that psychiatric diseases are characterized by groups of molecular abnormalities that indi- Figure 5 Pair-wise classification and regression tree for bipolar disorder compared to major depression.
vidually produce a small effect on the clinical phenotype. Clinical heterogeneity may depend on the combination and degree of these abnormalities. Secondly, abnormalities seen in the psychiatric groups tend to be decreased relative to normal controls. The directionality of the abnormalities argues against a purely stochastic explanation for these observations and suggests a widespread failure of gene expression in these diseases, perhaps due to some overriding insult such as infection, malnutrition, hypoxia, or a failure of the primary levels of control of gene expression. It is also possible that the decrease in gene expression is a consequence of the underlying disease process or its treatment, rather than a group of causative abnormalities occurring prior to disease onset. Thirdly, schizophrenia is associated with the greatest number of abnormalities (12), followed by bipolar disorder (8) and depression (5) . This pattern of abnormalities is consistent with clinical notions regarding the severity and functional consequences of these diseases and would also seem unlikely to be due solely to false positive statistical artifacts. Finally, schizophrenia and bipolar disorder overlap to a much greater degree (eight shared abnormal markers), than do bipolar disorder and depression (three shared abnormal markers). This suggests that current notions about the phenomenological segregation of these diseases may not be maintained at the molecular level.
A different set of variables emerged in the CRT analyses. In contrast to the findings observed with sequential analyses of variance, the CRT technique identified variables that were mainly related to GABA, glutamate and dopaminergic neurotransmission (see Table 6 ). In the CRT analysis of the four diagnostic groups, 45% of subjects were correctly classified in the test paradigm. This degree of classification is significantly better than chance (P Ͻ 0.05), but of relatively low utility if one were to imagine these markers as Figure 6 Pair-wise classification and regression tree for major depression compared to schizophrenia. schizophrenia and normal in both learning and test CRT paradigms. Similar to the conclusions stated above regarding the ANOVA results, the CRT technique had difficulty segregating schizophrenia from bipolar disorder (53.3% correct in the test model, not significantly better than chance), but also did not reliably discriminate depression from bipolar disorder (63.3% correct, not significantly better than chance). However, the CRT technique did reliably discriminate schizophrenia from depression (83.3% correct, significantly better than chance, P Ͻ 0.001).
Of interest was the relative lack of overlap between abnormal markers seen with ANOVA, and those markers that contributed maximally to correct diagnostic classification by CRT. Of the 14 abnormal ANOVA results and the nine classification markers found by CRT, only three overlapped (GAD 67, GR RNA in layer 6, and iNOS). These first two of these markers provided a significant contribution to the 4-group CRT run, and were present in five of the six pair-wise CRT runs. The lack of overlap is perhaps to be expected since markers that emerge after the first branch point in the decision tree are examined with respect to a subset of the initial group of subjects. For this reason, the markers that emerge from CRT analysis follow a type of logic that is appealingly similar to the way clinicians narrow the possibilities of differential diagnosis. A detailed description of the biological significance of all markers that emerged on the CRT analyses is beyond the scope of this paper, but a cursory description follows.
GAD 67 levels were the single most useful marker in making discriminations amongst these diseases. This variable emerged in the classification trees contrasting the four diagnostic groups, and in the pair-wise trees discriminating bipolar disorder from normal and from depression, and schizophrenia from normal and from depression. Reductions in mRNA for GAD 67 have been described in two other brain collections and in a previous publication using the Stanley Consortium. Akbarian et al 8 described reduced levels of mRNA for GAD 67 using in situ hybridization in 10 subjects with schizophrenia. The reduction in expression of GAD 67
was not accompanied by cell loss, and the authors concluded that an activity-dependent reduction of gene expression explained their observations. Volk et al, 9 in a separate cohort of 10 subjects, found a similar reduction in expression of GAD 67 RNA by in situ hybridization, with no change in the density of label per neuron. These authors concluded that a subset of GABA-ergic interneurons expresses markedly reduced amounts of GAD 67. Using the Stanley Consortium, Guidotti et al 10 described a reduction in GAD 67 mRNA by polymerase chain reaction, and a reduction of GAD 67 protein by Western blot in both schizophrenia and bipolar disorder. Taken together, these reports are amongst the most consistent findings in neuropathological studies of major mental illness.
Because GAD 67 levels were reduced only in subjects who had received antipsychotic drugs, it is possible that drug treatment induced a downregulation of GAD 67 protein. In this collection, GAD 67 levels were not significantly correlated with estimated lifetime exposure to antipsychotic drugs, but subjects exposed to antipsychotics had significantly lower levels (0.54, SD = 0.36) than those who had not received these drugs (1.06, SD = 0.52, P Ͻ 0.001). Volk et al 9 treated four non-human primates with haloperidol and were unable to demonstrate an effect on GAD 67 RNA expression in prefrontal cortex. Guidotti et al 10 found no differences in GAD 67 RNA expression when subjects from the Stanley Consortium were divided into three groups (clozapine only, n = 4; other neuroleptics, n = 15, or clozapine + other neuroleptics, n = 3), but this approach lacks robust statistical power. Sakai et al 11 have shown a variable pattern of GAD 67 RNA expression in subcortical structures of antipsychotictreated rodents (increased in striatum and thalamus and decreased in globus pallidus). Similar studies in cortical structures are not available. Further studies will be needed to determine if antipsychotic or other psychotropic drug treatment can influence GAD 67 levels, or if the level of GAD 67 can predict responsiveness to drug treatment.
Glucocorticoid receptor mRNA in layer 6 was the second most common variable present in the CRT analyses. This marker was present in the 4-group classification tree and in pair-wise trees discriminating schizophrenia from normal and depression from normal. The CRT analysis is congruent with a previous study, in which there were significantly reduced levels of GR RNA in the deep cortical layers of subjects with schizophrenia and depression compared to controls. 12 A reduction in GR RNA levels is hypothesized to be due to circulating hypercortisolemia associated with these illnesses, and seems unlikely to be due to specific cytoarchitectural abnormalities. Although antidepressant drugs and mood stabilizers increase GR number in rodent brain, we were unable to demonstrate robust effects of these drugs on this measure. Alterations in GR RNA levels are unlikely to be due to exposure to antipsychotics as the depressed subjects had not been exposed to these drugs. The significance of the abnormal expression of GR in layer 6 remains unknown. One speculative interpretation is that corticothalamic projections from layer 6 are more profoundly affected than other cortical areas, but further work will be necessary to clarify this issue.
The NR2C subunit of the ionotropic NMDA glutamate receptor in cortical layer 4 appeared in the classification tree differentiating the four diagnostic groups. The NMDA receptor is composed of four or five subunits in various combinations, which are regulated in a complex fashion, 13, 14 and which subserve a number of neural and glial functions. 15 In this classification tree, NR2C RNA expression above the established cutpoint favored a diagnosis of bipolar disorder, and levels below the cut-point favored a diagnosis of schizophrenia. Reduced expression of NR2C subunit in the frontal cortex in schizophrenia has been reported previously. 16 The cytoarchitectural specificity of the NR2C abnormality is currently unknown, but the fact that NR2C subunit expression was abnormal in layer 4 may indicate that thalamocortical glutamatergic projections are dysregulated in the major psychiatric illnesses.
Because most of the subjects with bipolar disorder and all of the subjects with schizophrenia had received antipsychotic drugs, it is unlikely that exposure to these drugs contributed to the classification advantage of NR2C. Estimated lifetime exposure to neuroleptics did not correlate with the level of NR2C expression (r = −0.15), and there was no significant difference between the level of NR2C expression in those subjects who had received antipsychotics and those who had not (P = 0.18). However, previous reports have shown that some antipyschotics reduce the expression of NR2C subunit in frontal cortex 17 and nucleus accumbens. 18 Animal studies have also suggested that administration of antidepressants reduces RNA expression of NMDA receptor subunits or radioligand binding to protein products of these mRNAs. 19, 20 There was a significant difference between subjects who had received antidepressants (eight bipolars, 10 depressed, four schizophrenics), and those who had not received these drugs (0.027, SD = 0.02 vs 0.038, SD = 0.02 respectively, P = 0.02), however most of these patients had received combinations of multiple drugs. These data are far from conclusive, but suggest that down-regulation of the NR2C subunit by antidepressant drugs may be an important feature for psychotherapeutic action. There was no significant difference between subjects who had received mood stabilizers (lithium, valproate, carbamazepine) and those who had not.
A subunit of the AMPA glutamate receptor, GluR2, emerged in the classification tree discriminating depression from normal. Again, this abnormality was confined to layer 6 and putatively implicates an abnormal regulation of corticothalamic projections in major depression. It is not possible to determine if reduced levels of GluR2 subunits in depression are due to an altered concentration of 'flip' or 'flop' splice variants in this illness. Expression of GluR2 subunits has been shown to be regulated by exposure to antipsychotic drugs; 21 however, depressed subjects were specifically excluded from this collection if they had received antipsychotic drugs. Specific effects of antidepressants and mood stabilizers on AMPA receptor units have not been reported in the literature. Likewise, there was no significant difference between subjects receiving antidepressants at the time of death and those who were not. Inducible nitric oxide synthetase protein (iNOS) was present in the classification tree discriminating bipolar disorder from depression. Levels of iNOS above the selected cut-point suggested a diagnosis of depression, and we have previously reported a statistical difference between depressed and normal subjects on this measure. 2 Inducible NOS is present in macrophages at low levels, but expression of this enzyme increases in response to stimuli such as lipopolysaccharide from Gram-negative bacteria or cytokines. With induction of iNOS, nitric oxide (NO) is generated, which has antibiotic properties, but which may also be neurotoxic. 22 No differences between treated and untreated subjects were observed for antipsychotics, antidepressants, or mood stabilizers. There was also no correlation between lifetime exposure to antipsychotics and iNOS protein level. The relevance of activated NO transmission for serious psychiatric illness requires further research.
Alpha-synuclein RNA emerged in the classification tree discriminating schizophrenia from depression, with higher levels favoring the diagnosis of schizophrenia. Abnormal deposition of ␣-synuclein is present in a number of degenerative neurological conditions. This protein is the main constituent of Lewy bodies and dystrophic neurites in Parkinson's disease and diffuse Lewy body disease, is present in the neuronal and glial inclusions seen in multiple system atrophy, and is also a component of senile plaque amyloid in Alzheimer's disease. 23 No differences between treated and untreated subjects were observed for antipsychotics, antidepressants, or mood stabilizers . There was also no correlation between lifetime exposure to antipsychotics and ␣-synuclein expression. Although inclusion bodies are not seen in the major psychiatric illnesses, it is possible that abnormal regulation of this protein may contribute to a failure of dendritic arborization or synaptogenesis in these disorders.
Two metabolites of dopamine emerged in the pairwise classification trees. S-cysteinyl DOPA (Ldihydroxyphenylalanine) was present in the tree discriminating schizophrenia from depression, with relatively higher levels of this compound being present in schizophrenia. DOPA is converted to dopamine by dopa decarboxylase. The s-cysteinyl adducts of catechols are produced following non-enzymatic auto-oxidation and are thought to be toxic and mutagenic compounds. 24, 25 These compounds, or their precursors, have previously been shown to discriminate post-mortem samples from schizophrenia and controls. 26, 25 Proposed mechanisms for these findings have included: lack of normal antioxidant capacity; reduced capacity to metabolize s-cysteinyl adducts; or increased synthesis of cysteine from homocysteine and methionine, Molecular Psychiatry in schizophrenia. There was no correlation between Scysteinyl DOPA levels and lifetime exposure to antipsychotics. There was a significant difference (P = 0.04) in mean levels between the groups who had received antipsychotic drugs (8.39, SD = 2.87) and those who had not (6.86, SD = 2.50), suggesting that antipsychotic treatment may independently increase the formation of this metabolite. No differences between treated and untreated subjects were observed for antidepressants or mood stabilizers.
S-cysteinyl DOPAC (dihydroxyphenylacetic acid) was present in the classification tree discriminating bipolar disorder from depression, with higher levels favoring a diagnosis of bipolar disorder. DOPAC is a metabolite of dopamine produced by monamine oxidase. There was no correlation between S-cysteinyl DOPA levels and lifetime exposure to antipsychotics. No differences between treated and untreated subjects were observed for antipsychotics, antidepressants, or mood stabilizers.
One other interesting capacity of the Stanley Consortium is the ability to examine the effects of inter-assay variability on the reproducibility of post-mortem findings. For example, in this summary three separate laboratories made Western blot analyses of GSK-3␤, albeit in slightly different areas of prefrontal cortex. One of these data sets revealed a significant reduction in the schizophrenic subjects compared to controls. 27 The other two data sets failed to confirm this finding. The three data sets were also poorly correlated with one another (r values ranged from 0.07 to 0.24). This discrepancy may be explained by variance in assay conditions across labs, or variance depending on anatomical differences in the tissues used in these labs. These divergent results are being evaluated further by the investigators.
In summary, we have shown with this overview that the CRT system of analysis selects quite a different list of post-mortem variables than did sequential analyses of variance. These variables are perhaps more consistent with traditional neurotransmitter models of severe mental illness that propose a dysregulation of dopaminergic, glutamatergic and GABA-ergic pathways. Nevertheless, the abnormal variables that have been presented here may all be viewed as potential sites for new therapeutic drugs, for candidate genes, or for predictors of response to psychotropic drugs. We hope that this summary will stimulate further research along these lines.
